enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Moderate Buy” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has been given a consensus rating of “Moderate Buy” by the nine analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $23.2857.

ENGN has been the topic of a number of recent analyst reports. Citigroup reissued a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Raymond James Financial raised shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price target for the company in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a research note on Friday, January 9th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of enGene in a research report on Wednesday, December 3rd. Finally, Jefferies Financial Group began coverage on shares of enGene in a research note on Friday, January 30th. They set a “buy” rating and a $28.00 price target for the company.

enGene Trading Down 10.6%

NASDAQ:ENGN opened at $8.71 on Friday. The firm has a market capitalization of $583.48 million, a price-to-earnings ratio of -3.80 and a beta of -0.29. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $9.60 and its two-hundred day moving average price is $7.98. enGene has a 1-year low of $2.65 and a 1-year high of $12.25.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). On average, equities analysts expect that enGene will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On enGene

Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in enGene during the 4th quarter valued at $216,000. Vestal Point Capital LP lifted its holdings in shares of enGene by 185.1% during the 4th quarter. Vestal Point Capital LP now owns 1,055,000 shares of the company’s stock worth $9,527,000 after acquiring an additional 685,000 shares during the last quarter. Virtus Investment Advisers LLC purchased a new position in shares of enGene in the 4th quarter worth about $284,000. Quadrature Capital Ltd purchased a new position in shares of enGene during the fourth quarter worth approximately $439,000. Finally, Perceptive Advisors LLC lifted its stake in enGene by 179.8% in the fourth quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after purchasing an additional 3,771,840 shares during the last quarter. Institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.